Missouri's final fairness hearing on Bayer's $7.25B Roundup settlement faces over 100 objections targeting opt-out terms, notice failures, and a $675M fee request.
The 22nd Judicial Circuit Court of Missouri held a final fairness hearing July 9 on Bayer AG's proposed $7.25 billion class settlement resolving non-Hodgkin's lymphoma claims tied to its Roundup weed killer [1]. The settlement would cover both current plaintiffs and future claimants diagnosed within a 16-year window following approval [1]. The hearing marks the most consequential procedural moment yet in litigation that has generated tens of thousands of lawsuits against Bayer's subsidiary Monsanto since glyphosate, Roundup's active ingredient, was linked to cancer risk [1].
The proposed resolution faces substantial resistance. More than 100 class members and roughly a dozen health care plans filed formal objections ahead of the hearing, raising concerns about inadequate notice to class members, an onerous opt-out process, inconsistent treatment of claimants within the same class, and a $675 million attorney fee request [1]. Federal MDL Judge Vince Chhabria, overseeing parallel Roundup litigation in federal court, has publicly criticized the opt-out provisions applicable to future claimants as unworkable, adding pressure on the state court to scrutinize those terms [1]. Bayer successfully argued earlier this year to keep the settlement proceedings in Missouri state court rather than transfer them to federal court, a venue dispute the company resolved in its favor in June [2].
The stakes extend well beyond this hearing. Approximately 65,000 pending Roundup claims could be resolved, modified, or redirected depending on the court's ruling [1]. The settlement's structure for future claimants carries particular significance given the pending Supreme Court case Monsanto v. Durnell, which may clarify federal preemption standards for state-law failure-to-warn claims against pesticide manufacturers [1]. A rejection or substantial modification of the settlement could force Bayer to relitigate those claims individually, a prospect the company has worked to avoid following several high-profile trial losses and prior settlement collapses.
Bayer Chief Executive Bill Anderson has publicly tied resolution of the Roundup litigation to the company's broader financial stabilization strategy [1]. If Judge Timothy Boyer approves the settlement over the filed objections, the company would close one of the most protracted mass-tort disputes in U.S. corporate history, at least for current plaintiffs [1]. A ruling is expected in the weeks following the hearing, though the volume of objections and the complexity of the future-claimant provisions could extend that timeline.